Company news

Starpharma Holdings Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

SPL7013 nasal spray for COVID19 development update

August 25, 2020

Starpharma signs new DEP partnership with Chase Sun

August 16, 2020

DEP irinotecan boosts immuno-oncology in colon cancer models

June 28, 2020

DEP products showcased at AACR 2020

June 22, 2020

DEP lutetium effective in human prostate cancer model

June 17, 2020

VivaGel BV launched in central and eastern Europe

June 16, 2020

DEP irinotecan phase 2 commences after positive phase 1

May 7, 2020

SPL7013 shows significant activity against coronavirus

April 15, 2020

Quarterly Cashflow and Activity Report

April 7, 2020

Okamoto licenses VivaGel antiviral condom in Asian countries

March 3, 2020

VivaGel BV launched in Asia

February 12, 2020

Starpharma receives US$3M milestone from AstraZeneca

February 10, 2020

Quarterly Cashflow Report

January 28, 2020

Commencement of phase 1 trial for AZD0466 utilising DEP

December 29, 2019

Starpharma receives $4.9M R&D tax incentive refund

December 15, 2019

DEP cabazitaxel progresses to phase 2 on positive results

December 9, 2019

AGM - Chairman address and CEO presentation

November 21, 2019

VivaGel condom receives regulatory approval in Europe

November 20, 2019

UK launch of VivaGel BV

November 12, 2019

DEP outperforms Gemzar in human pancreatic cancer model

October 30, 2019

FDA Authorises Clinical Trial with AstraZeneca DEP product

September 25, 2019

DEP irinotecan synergistic with Lynparza in refractory model

September 12, 2019

VivaGel BV regulatory approvals continue in Asia

September 2, 2019

Positive results with Targeted DEP using antibody fragment

August 29, 2019

Promising efficacy signals observed in ongoing DEP trials

August 27, 2019

First Asian Regulatory Approvals Received for VivaGel BV

August 14, 2019

Starpharma commences phase 1/2 DEP irinotecan trial

August 7, 2019

VivaGel BV launched in Europe

June 27, 2019

Starpharma signs second oncology agreement with AstraZeneca

June 2, 2019

DEP irinotecan combination outperforms in colon cancel model

May 24, 2019

First VivaGel BV launch globally in Australia by Aspen

April 16, 2019

Starpharma receives $4.0M R&D tax incentive refund

March 11, 2019

Interim Report and Half-Yearly Financial Results

February 26, 2019

Response to ASX Aware Letter

January 7, 2019

VivaGel condom receives final regulatory approval in Japan

January 1, 2019

US FDA requests further data for VivaGel BV approval

December 27, 2018

US VivaGel BV licensed for A$142M milestones plus royalties

December 19, 2018

DEP products outperform in human pancreatic cancer model

November 16, 2018

Starpharma Investor Presentation for Citi Conference

October 16, 2018

DEP irinotecan outperforms in pancreatic cancer model

September 5, 2018

AstraZeneca DEP Bcl2/xL inhibitors show compelling efficacy

August 31, 2018

Annual report and full year financial results

August 21, 2018

VivaGel BV NDA advances to next stage of FDA review

July 9, 2018

Starpharma licenses VivaGel BV to Mundipharma for Europe

June 26, 2018

Mundipharma licenses Starpharmas VivaGel BV

May 3, 2018

Appendix 4C - Quarterly Cashflow Report

April 30, 2018

Starpharma completes US New Drug Application for VivaGel BV

April 29, 2018

Starpharma receives $3.7M R&D tax incentive refund

February 21, 2018

Starpharma to commence DEP cabazitaxel phase 1/2 trial

January 31, 2018

VivaGel BV treatment clinical submission under rolling NDA

December 20, 2017

← Newer news releases · Older news releases →

Decks

The 5 newest of 51 decks. Every deck is listed under its year.